Quick Answer
Camp4 Therapeutics Corp reported Operating Income Loss of -$52.56 million for the year ending 2025.
- Camp4 Therapeutics Corp showed an increase of +1.0% in Operating Income Loss from 2024 to 2025.
- This data is from Camp4 Therapeutics Corp's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: -$12.34 million | Q1 2024: -$12.88 million | Q2 2024: -$12.66 million | Q3 2024: -$13.52 million | Q1 2025: -$13.10 million | Q2 2025: -$13.03 million | Q3 2025: -$13.65 million.
- Over the full 3 years of available data (2023 to 2025), Camp4 Therapeutics Corp's Operating Income Loss has declined by 1.3%.
- Historical annual values: Fiscal year 2025: -$52.56 million | Fiscal year 2024: -$53.09 million | Fiscal year 2023: -$51.88 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: